ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 626 • 2017 ACR/ARHP Annual Meeting

    Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

    Désirée van der Heijde1, Masato Okada2, Chin H. Lee3, Catherine Shuler3, Suchitrita Rathmann3, Chen-Yen Lin3 and Philip J Mease4, 1Leiden University Medical Center, Leiden, Netherlands, 2Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 3Eli Lilly and Company, Indianapolis, IN, 4Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint…
  • Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting

    Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission

    Clothilde Barral1, David Hajage2, Bruno Fautrel3, Pierre Lafforgue1, Florence Tubach2 and Thao Pham1, 1Rheumatology, APHM, Aix Marseille Univ, Marseille, France, 2APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, 3Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France

    Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
  • Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting

    Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Joel Kremer1, William F C Rigby2, Nora Singer3, Christine Birchwood4, Darcy Gill4, William Reiss4, Jinglan Pei4 and Margaret Michalska4, 1Albany Medical College, Albany, NY, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
  • Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting

    Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab

    Laura C Coates1, Proton Rahman2, Eliofotisti Psaradellis3, Emmanouil Rampakakis3, Brendan Osborne4, Allen J Lehman5 and Francois Nantel4, 1LIRMM, University of Leeds, Leeds, United Kingdom, 2Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 3JSS Medical Research, Montreal, QC, Canada, 4Medical Affairs, Janssen Inc., Toronto, ON, Canada, 5Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
  • Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting

    Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom

    Lianne Kearsley-Fleet1, Diederik De Cock1, Eileen Baildam2, Michael W. Beresford3, Helen E. Foster4, Taunton R. Southwood5, Wendy Thomson6,7 and Kimme L. Hyrich1,6, 1Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 3Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 4Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, 5Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 6National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 7Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
  • Abstract Number: 637 • 2017 ACR/ARHP Annual Meeting

    The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis

    Julia Manasson1, Carles Ubeda2, Lu Yang3, Melania Fanok4, Gary E. Solomon1, Soumya M. Reddy5, Sergei Koralov6, Jose C. Clemente7 and Jose U. Scher1,4, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Institute for Research in Public Health, Valencia, Spain, 3New York University School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, 6Pathology, New York University School of Medicine, New York, NY, 7Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. If left untreated, it has the potential for significant morbidity and disability.…
  • Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting

    Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice

    Takaaki Komiya1, Kaoru Minegishi-Takase2, Natsuki Sakurai1, Yuichiro Sato1, Hideto Nagai3, Naoki Hamada3, Yumiko Sugiyama3, Naomi Tsuchida1, Yutaro Soejima3, Yosuke Kunishita3, Hiroto Nakano3, Daiga Kishimoto3, Koji Kobayashi2, Reikou Kamiyama3, Ryusuke Yoshimi3, Yukiko Asami3, Yohei Kirino3, Shigeru Ohno4 and Hideaki Nakajima3, 1Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

    Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
  • Abstract Number: 1966 • 2017 ACR/ARHP Annual Meeting

    Risk of Tuberculosis in Biologic Users for Rheumatic Diseases: Results from the South African Biologics Registry

    Clive Pettipher1 and Romela Benitha2, 1Rheumatology, Private Practice, Stellenbosch, South Africa, 2Rheumatology, Private Practive, Johannesburg, South Africa

    Background/Purpose: To evaluate the rate of tuberculosis (TB) in biologic users for rheumatic diseases in South Africa, a TB endemic country, the effectiveness of our…
  • Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting

    Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients

    Laura C Coates1, Ana-Maria Orbai2, Julie Birt3, Lisa Kerr3, Olivier Benichou3 and Philip S. Helliwell4, 1University of Oxford, Leeds, Great Britain, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Eli Lilly and Company, Indianapolis, IN, 4School of Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
  • Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting

    Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate

    Michael D. George1, Brian Sauer2, Chia-Chen Teng, MS2, Grant Cannon2, Bryant R. England3, Gail S. Kerr4, Ted R. Mikuls5 and Joshua Baker6, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4VAMC, Georgetown University, Washington, DC, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
  • Abstract Number: 925 • 2017 ACR/ARHP Annual Meeting

    Open-Source Conensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care

    Devin Incerti1, Jeffrey R. Curtis2, Maria Lorenzi1 and Jeroen Jansen1, 1Innovation and Value Initiative, Oakland, CA, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The treatment and prognosis of moderate to severe rheumatoid arthritis has improved considerably due to the advent of biological therapies. But at the same…
  • Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting

    Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis

    Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan

    Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
  • Abstract Number: 2024 • 2017 ACR/ARHP Annual Meeting

    Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial

    Hannah Schenker1, Andreas Hess2, Laura Konerth2, Marina Sergeeva2, Jutta Prade2, Arnd Kleyer1, Michaela Reiser1, Axel J. Hueber1, Matthias Englbrecht1, Eugen Feist3, Reinhard Voll4, Bettina Bannert4, C Baerwald5, Julie Rösch6, Arnd Dörfler7, José António P. da Silva8, Nemanja Damjanov9, Georg Schett1 and Juergen Rech1, 1Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Institute of Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Rheumatology and Clinical Immunology, Charité, Berlin, Berlin, Germany, 4Clinic for Rheumatology and Clinical Immunology, Medical University of Freiburg, Germany, Freiburg, Germany, 5Department of Rheumatology, University of Leipzig, Germany, Leipzig, Germany, 6Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, 7Department of Neuroradiology, University of Erlangen-Nuremberg, Germany, e, Germany, 8Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 9Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) signify a major advance in the treatment of rheumatoid arthritis (RA). However, treatment success initially remains uncertain as one…
  • Abstract Number: 2591 • 2017 ACR/ARHP Annual Meeting

    Association of Smoking and Cutaneous Manifestations in Systemic Lupus Erythematosus (SLE): Post-Hoc Results from Phase IIb Studies of Anifrolumab and Sifalimumab

    Victoria P Werth1, Gabor Illei2, Gabriel Abreu3, Liangwei Wang2 and Warren Greth2, 1University of Pennsylvania and the VA Medical Center, Philadelphia, PA, 2MedImmune, Gaithersburg, MD, 3AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Studies have demonstrated an association between smoking and more severe cutaneous lupus erythematosus, resulting in decreased health-related quality of life and treatment response.1 We…
  • Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting

    Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards

    Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan

    Background/Purpose:  Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology